Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC7 ion channels
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 4, 2013
Grant Date -
Jan 20, 2011
app pub date -
Oct 14, 2008
filing date -
Oct 26, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond. The present invention provides a pharmacological tool compound that allows to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. In the present invention, norgestimate is shown to selectively inhibit TRPC3, TRPC6 and TRPC7.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully